Carfilzomib

3:08
Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel
1:07
Drug cost vs. toxicity in MM
Hareth Nahi
1:24
New therapies for MM
Guy Pratt
4:13
Autologous transplant advances: induction and maintenance
Paul Richardson
4:44
KEYNOTE-183 and OPTIMISMM: creating new standards of care for R/R MM
Maria-Victoria Mateos
2:54
ARROW: once vs. twice weekly carfilzomib for MM
Maria-Victoria Mateos
1:21
ENDEAVOUR: carfilzomib/dexamethasone therapy for relapsed MM
Rakesh Popat
1:28
Using carfilzomib/dexamethasone for MM in the real world
Rakesh Popat
1:28
Promising new therapies for multiple myeloma
Faith Davies
2:12
T-cell redirecting therapies for R/R multiple myeloma
Niels van de Donk
1:43
Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
Torben Plesner
2:22
Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
Graham Jackson
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
2:45
MRD-guided high-dose carfilzomib treatment for multiple myeloma
Ola Landgren
4:48
Curative strategy for smoldering multiple myeloma: GEM-CESAR
Maria-Victoria Mateos
1:04
Results of the ASPIRE trial for MM: the addition of carfilzomib
Greg Friberg
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals